MYX.AX - Mayne Pharma Group Limited

ASX - ASX Delayed price. Currency in AUD
0.64
+0.00 (+0.79%)
At close: 3:59PM AEDT
Stock chart is not supported by your current browser
Previous close0.63
Open0.64
Bid0.67 x 4555600
Ask0.59 x 509100
Day's range0.63 - 0.64
52-week range0.59 - 1.59
Volume3,726,825
Avg. volume7,741,798
Market cap986.566M
Beta1.88
PE ratio (TTM)10.49
EPS (TTM)0.06
Earnings date19 Feb. 2018 - 23 Feb. 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.76
  • These 2 cryptocurrencies have smashed Bitcoin’s returns in 2017
    Motley Fool4 hours ago

    These 2 cryptocurrencies have smashed Bitcoin’s returns in 2017

    2 cryptocurrencies that have returned more than 3,000% in 2017 and outperformed Bitcoin in the process.

  • Mayne Pharma expects "soft" H1 to improve
    AAP14 days ago

    Mayne Pharma expects "soft" H1 to improve

    Drugs manufacturer Mayne Pharma is still feeling the impact of tough competition and lower prices in the generic drugs market in the US, but expects the release of new drugs and restructuring initiatives will boost the company's financial performance. Chief executive Scott Richards says the company's first half is expected to be "soft" but that a range of initiatives is already yielding benefits. Shares in Mayne Pharma dropped 1.5 cents, or 2.4 per cent, to 61 cents.

  • AAP14 days ago

    Mayne Pharma warns of 'soft' first half

    Mayne Pharma's revenue for the first four months of the financial year dropped 12 per cent due to price deflation in the US generic marketplace. Chief executive Scott Richards says group revenue to the ...

  • Motley Fool2 months ago

    These 3 small cap stocks could be big winners

    3 small cap stocks that could perform well including Mayne Pharma Group Ltd (ASX:MYX).

  • noodls11 months ago

    Change of Director's Interest Notice

    Appendix 3Y Appendix 3Y Rule 3.19A.2 Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public. ...

  • noodls11 months ago

    Appendix 3B

    vRule 2.7, 3.10.3, 3.10.4, 3.10.5 New issue announcement, application for quotation of additional securities and agreement Information or documents not available now must be given to ASX as soon as available. ...

  • noodlslast year

    Change in substantial holding from CBA

    F-4861 FORM 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder To: Company Name/Scheme: MAYNE PHARMA GROUP LIMITED ACN/ARSN: 115 832 963 1. Details of substantial ...

  • noodlslast year

    Change of Director's Interest Notice (x4)

    Appendix 3Y Change of Director's Interest Notice Rule 3.19A.2 Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property ...

  • noodlslast year

    Appendix 3B

    vRule 2.7, 3.10.3, 3.10.4, 3.10.5 New issue announcement, application for quotation of additional securities and agreement Information or documents not available now must be given to ASX as soon as available. ...

  • noodlslast year

    Change of Director's Interest Notices (x2)

    Appendix 3Y Change of Director's Interest Notice Rule 3.19A.2 Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property ...

  • noodlslast year

    UPDATE ON STATUS OF DOJ INVESTIGATION

    ASX Announcement 16 December 2016, Adelaide Australia: Mayne Pharma Group Limited previously disclosed that it was one of several generic companies to receive a subpoena from the Antitrust Division of ...